The prevalence of atopic dermatitis (AD) in industrialized nations is estimated at up to 30% for children and up to 10% for adults. The vast majority (85%) of affected patients develop symptoms before reaching their 5th birthday. For children, severity can increase with age although in 70% of childhood cases AD remits by adolescence. Allergist/immunologists often receive referrals of these challenging cases from other clinicians, and it is essential that they and the other health care providers working with them be prepared to provide optimal treatment to these patients.

To clarify these challenges, the American Academy of Allergy, Asthma & Immunology and The France Foundation have designed a certified medical education initiative through which non-dermatology specialists can increase their knowledge, confidence and competence in the diagnosis and treatment of patients with AD. This will activity will highlight the diagnosis and treatment of AD in children.

Supported by an educational grant from Pfizer.

The following is a link to the abstract of a companion article printed in the Journal of Clinical Allergy: In Practice

Update on Atopic Dermatitis: Diagnosis, Severity Assessment, and Treatment Selection

TARGET AUDIENCE

• Allergist/immunologists
• Fellows-in-Training
• Nurses and Nurse Practitioners
• Physician Assistants and Other Allied Health Professionals

LEARNING OBJECTIVES

Upon completion of the activity, participants should be able to:

• Diagnose AD chiefly on the basis of the clinical exam
• Evaluate severity on the basis of provided criteria and evaluation tools, as appropriate
• Address exacerbations appropriately, on the basis of evidence and recommendations
• Select treatment for moderate-to-severe AD on the basis of available data

CONTENT DEVLOPERS

Anna Fishbein, MD
Northwestern University Feinberg School of Medicine, Chicago, IL
Relevant relationships: None

Peck Ong, MD FAAAAI
Los Angeles Children's Hospital and USC Keck School of Medicine, Los Angeles, CA
Relevant relationships: Pfizer (grant reviewer); Regeneron (research funding); Abbvie (consultant)

Anne Russell, MS BSN RN AE-C
Spring Arbor University, Spring Arbor, MI
Relevant relationships: None

Jonathan I. Silverberg, MD PhD MPH
Northwestern University Feinberg School of Medicine
Relevant relationships: Abbvie, AnaptysBio, Asana BioSciences, Eli Lilly, Galderma, GSK, Kiniksa, Leo Pharma, Realm Pharaceuticals, Sanofi Regeneron Pharmaceuticals (consultant)

Carrie Burton
The France Foundation, Old Lyme, CT
Relevant relationships: None

Eve Wilson, PhD
The France Foundation, Old Lyme, CT
Relevant relationships: None

CONTENT REVIEWERS

Stuart Abramson, MD FAAAAI
Shannon Medical Center, San Angelo, TX
Relevant relationships: None

Karen Gregory, DNP APRN-BC RRT AE-C
Oklahoma Allergy and Asthma Clinic, Edmond, OK
Relevant relationships: None

AAAAI DISCLOSURE POLICY

Pursuant to the Code of Ethics for the American Academy of Allergy, Asthma & Immunology (AAAAI) and the Standards for Commercial Support of Continuing Medical Education of the Accreditation Council for Continuing Medical Education, the AAAAI requires disclosure of certain information from faculty members of educational activities designated for CME credit by the AAAAI. Prior to the activity, authors and reviewers are required to disclose all relationships that meet the following parameters:

• Employment: Name of employer and job title.
• Financial interests: All organizations, other than the employer, from which the faculty member or a member of his/her immediate family or household receives annual remuneration in any amount (including grants, honoraria and consulting fees).
• Research interests: All organizations which support research projects for which the faculty member or member of his/her immediate family or household serves as an investigator.
• Legal Consultation Services/Expert Witness Testimony: All topics on which the faculty member provided legal consultation and/or expert witness testimony during the previous calendar year.
• Organizational interests: All organizations, other than the AAAAI, for which the faculty member holds volunteer positions.
• Gifts: All organizations from which the faculty member or a member of his/her immediate family or household have received a gift of any amount in the last year.
• Other interests: All interests of the faculty member or a member of his/her immediate family or household that would be judged by a majority of his/her peers to be more than casual and/or likely to impact his/her ability to exercise independent judgment. This includes any financial interest in or relationship with any manufacturer of a commercial product, and any financial interest or relationship with any organization that provides commercial support to AAAAI-sponsored educational activities.

The information disclosed by the speakers and planning committee was reviewed in accordance with the AAAAI Disclosure Policy. All potential conflicts of interest were resolved by the planners, faculty, and reviewers prior to their participation in the development of this activity

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AAAAI and The France Foundation. The AAAAI is accredited by the ACCME to provide continuing medical education for physicians.

DESIGNATION STATEMENT 

The American Academy of Allergy, Asthma & Immunology designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CE DESIGNATION STATEMENT

The American Academy of Allergy, Asthma, & Immunology (AAAAI) is a Provider, approved by the California Board of Registered Nursing, Provider #10704, for up to 0.50 Contact Hours.

CREDIT CLAIMING PERIOD

Credit claiming for this activity will expire at 11:59 pm on May 31, 2021. Requests to claim credit on or after May 31, 2021 will be denied.

AAAAI PRIVACY POLICY

To verify your participation in educational activities, you may be asked to provide your name, contact information, and/or other descriptors. The AAAAI will not release this information to outside entities. It may be used internally to inform you of other AAAAI educational activities. If you wish to have your information excluded from this process, please contact us at cme@aaaai.org.

QUESTION

Activity-related questions should be directed to  cme@aaaai.org.

AVAILABLE CREDIT

• 0.50 CME CME credit.

AAAAI PRIVACY AND DATA PROTECTION POLICY

The American Academy of Allergy, Asthma & Immunology (AAAAI) takes your privacy seriously. AAAAI will only use your personal information to administer your registration, attendance, and credit claiming/attendance record for this event (“the Course”), to provide services that you have requested from AAAAI and otherwise as you may expressly consent. A complete copy of AAAAI’s Privacy and Data Protection Policy, the terms of which are incorporated herein, can be found at: https://www.aaaai.org/global/disclaimer

By providing consent, you are allowing AAAAI and our educational partner(s) involved in this Course to process your personal data. AAAAI will collect and store information you provide in the Registration Form for the purposes of enabling us to register your attendance in this Course; to assist with administrative, planning and marketing purposes; and to allow the compilation and analysis of statistics relevant to AAAAI and our educational partner(s).

The information you provide in the Registration Form and information provided at any other time during the Course, including without limitation any feedback obtained during the Course, will be used by AAAAI to offer, provide and continue to improve this Course and other services. With your permission, the AAAAI may disclose some information that is collected in the Registration Form such as your name, organization, address, telephone and fax numbers, and email address to industry supporters (subject to conditions) for marketing purposes. The AAAAI will also use your email address to communicate important information regarding this event and for marketing purposes for future events.

AAAAI will not otherwise, without your consent, use or disclose your personal information for any purpose unless it would reasonably be expected that such a purpose is related to the offer, provision and improvement of the Course or where such purpose is permitted or required by law.

AAAAI emphasizes the fact that industry supporters of the Course may request that you share your contact information for the purpose of participating in a sponsored event outside of the Course agenda. This data transaction is considered a direct transfer of your information to the industry supporter. AAAAI does not control the usage of information transferred this way, and as such, AAAAI shall not be held responsible for any misuse of your personal data retrieved by industry supporters. You have the option to decline an industry supporter’s request to share your contact information and can ask them questions about how they will use your personal data, how long it will be retained and if they will share information with third parties.